TP53 and cancer: The MDM2-p53 binding antagonists were developed to bind to MDM2 in the p53-binding pocket, allow p53 to accumulate, and then activate the p53 pathway in cancer cells, resulting in cell cycle arrest and apoptosis or senescence, depending on the cell type.